MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Avidity Biosciences Inc

Ouvert

SecteurSoins de santé

30.93 2.55

Résumé

Variation du prix de l'action

24h

Actuel

Min

29.7

Max

31.1

Chiffres clés

By Trading Economics

Revenu

-22M

-102M

Ventes

637K

3M

BPA

-0.8

Marge bénéficiaire

-3,439.522

Employés

391

EBITDA

-23M

-120M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+121.09% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-214M

3.4B

Ouverture précédente

28.38

Clôture précédente

30.93

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Avidity Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 avr. 2025, 09:30 UTC

Actualités

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Comparaison

Variation de prix

Avidity Biosciences Inc prévision

Objectif de Prix

By TipRanks

121.09% hausse

Prévisions sur 12 Mois

Moyen 67.83 USD  121.09%

Haut 96 USD

Bas 48 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

12

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

25.8 / 31.58Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.